OTCMKTS:ACUR Acura Pharmaceuticals (ACUR) Stock Price, News & Analysis $0.0004 0.00 (0.00%) As of 06/18/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartHeadlinesSEC FilingsBuy This Stock About Acura Pharmaceuticals Stock (OTCMKTS:ACUR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Acura Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.0004▼$0.000450-Day Range N/A52-Week Range$0.0001▼$0.01VolumeN/AAverage Volume459 shsMarket Capitalization$26.66 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Acura Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products designed to deter prescription drug abuse and misuse. The company’s core business centers on proprietary drug formulations that incorporate its Aversion and ARCUS® abuse-deterrent technologies. These platforms are intended to make it more difficult to tamper with or extract active pharmaceutical ingredients from oral dosage forms, helping to address public health concerns around opioid and stimulant abuse. Acura’s lead product, Oxaydo®, is an immediate‐release oxycodone tablet that employs Aversion® technology to discourage tampering and intravenous abuse. In addition to Oxaydo®, the company has advanced a pipeline of collaborative research agreements with other pharmaceutical partners seeking to integrate Acura’s intellectual property into their own opioid and stimulant portfolios. Acura’s ARCUS® technology further expands its offerings by providing a nasal discomfort mechanism designed to deter intranasal abuse of solid dosage forms. Founded in 2001 and headquartered in Palatine, Illinois, Acura Pharmaceuticals serves markets across the United States and has established licensing relationships with both branded and generic drug manufacturers. The company operates under the leadership of an executive team with experience in pharmaceutical development, regulatory affairs and commercial strategy. Acura continues to pursue regulatory approvals, strategic collaborations and intellectual property development aimed at reducing the societal impact of prescription drug abuse.AI Generated. May Contain Errors. Read More Receive ACUR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acura Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ACUR Stock News HeadlinesAcura Pharmaceuticals (OTCMKTS:ACUR) Stock Crosses Above Two Hundred Day Moving Average - What's Next?June 17 at 2:57 AM | americanbankingnews.comAcura Pharmaceuticals Flags Ongoing SEC Filing DelaysMay 13, 2026 | tipranks.comBofA: Digital Dollar Coming 2025-2030The US government has ONLY ONE mathematical escape from $38.4T in debt: explosive AI-driven GDP growth. AI at scale (billions of autonomous machines transacting every second) can't run on Visa or ACH… It can't run on a banking system that closes at 5 PM… AI needs new financial infrastructure. June 23rd at 11 am ET, I'm revealing the exact convergence between America's debt crisis, AI infrastructure, and the ONE asset class the U.S. government has no choice but to fuel as trillions pour in.June 20 at 1:00 AM | Decentralized Masters (Ad)Acura Pharmaceuticals Secures Insider Loans Amid Liquidity StrainMay 7, 2026 | tipranks.comAcura Pharmaceuticals Inc.April 8, 2026 | barrons.comAcura Pharmaceuticals Relies on New AD Pharma FinancingJanuary 20, 2026 | tipranks.comAcura Pharmaceuticals Extends Key Financing Agreement with AD PharmaDecember 29, 2025 | tipranks.comAcura Pharmaceuticals Delays Q3 2025 Report FilingNovember 21, 2025 | tipranks.comSee More Headlines ACUR Stock Analysis - Frequently Asked Questions How have ACUR shares performed this year? Acura Pharmaceuticals' stock was trading at $0.0005 at the beginning of 2026. Since then, ACUR shares have decreased by 20.0% and is now trading at $0.0004. How were Acura Pharmaceuticals' earnings last quarter? Acura Pharmaceuticals, Inc. (OTCMKTS:ACUR) issued its quarterly earnings results on Friday, February, 28th. The specialty pharmaceutical company reported $0.00 EPS for the quarter. The specialty pharmaceutical company had revenue of $1.32 million for the quarter. Does Acura Pharmaceuticals have any subsidiaries? The following companies are subsidiaries of Acura Pharmaceuticals: Acura Pharmaceutical Technologies Inc.. How do I buy shares of Acura Pharmaceuticals? Shares of ACUR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Acura Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Acura Pharmaceuticals investors own include Denali Therapeutics (DNLI), Matinas Biopharma (MTNB), Corbus Pharmaceuticals (CRBP), Fulcrum Therapeutics (FULC) and Company Calendar Last Earnings2/28/2020Today6/20/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry MED - GENERIC DRG Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:ACUR Previous SymbolNASDAQ:ACUR CIK786947 Webwww.acurapharm.com Phone(847) 705-7709Fax847-705-5399Employees10Year Founded1935Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares66,650,000Free Float53,186,000Market Cap$26.66 thousand OptionableNot Optionable Beta-12.36 Social Links 10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free Report This page (OTCMKTS:ACUR) was last updated on 6/20/2026 by MarketBeat.com Staff. From Our PartnersBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredForget the million-dollar nest eggNearly 2 in 3 Americans fear running out of money more than death - and chasing a $1.5 million nest egg isn't ...Investors Alley | SponsoredThis is the worst news for stocks in 50 yearsGoldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...TradeSmith | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredHow to play the Biggest IPO in stock market history!SpaceX is eyeing a near-$2 trillion IPO valuation, and retail investors are already lining up - but early insi...InvestPub | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredRead this before you touch SPCXSPCX is live on Nasdaq - but a market expert who called AMD before it climbed as high as 7,100% says buying th...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acura Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acura Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
